Etanercept for the treatment of psoriasis in the elderly - 09/08/11
Reprint requests: Abby S. Van Voorhees, MD, University of Pennsylvania Department of Dermatology, 3600 Spruce St, 2M44, Philadelphia, PA 19104.Philadelphia, Pennsylvania and Thousand Oaks, California
Abstract |
This study’s objective was to analyze the effect of etanercept on Psoriasis Area and Severity Index (PASI) 50, PASI 75, and Dermatology Life Quality Index in geriatric and nongeriatric populations. We conducted a post hoc analysis of two large phase III randomized placebo trials of etanercept. There were no statistically significant differences between the elderly and young with regard to the number of patients reaching a PASI 50 or PASI 75 at any of the 3 dosing regimens. Baseline Dermatology Life Quality Index scores were not statistically significant between both groups and both the elderly and young had similar changes in Dermatology Life Quality Index with therapy. A limitation of the study was the small number of patients in the elderly group. In conclusion, psoriasis and its treatment has a similar impact on quality of life in the elderly as it does in the young.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Disclosure: Drs Xia and Stevens are employees of Amgen, the manufacturer of this compound. Dr Van Voorhees has served as a consultant for Amgen and on the advisory board for Genentech; received clinical grants from Genentech, BiogenIDEC, and Bristol Myers Squibb; and served on the speaker’s bureau for BiogenIDEC, Amgen, and Genentech. |
Vol 55 - N° 3
P. 517-519 - septembre 2006 Retour au numéro
Article précédent
- August Iotaderma (#151)
- Robert I. Rudolph
- Histopathologic findings in primary erythromelalgia are nonspecific: Special studies show a decrease in small nerve fiber density
- Mark D.P. Davis, Roger H. Weenig, Joseph Genebriera, Gwen Wendelschafer-Crabb, William R. Kennedy, Paola Sandroni
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?